Matches in Wikidata for { <http://www.wikidata.org/entity/Q65472656> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- Q65472656 description "clinical trial" @default.
- Q65472656 description "ensayu clínicu" @default.
- Q65472656 description "klinisch onderzoek" @default.
- Q65472656 description "клінічне випробування" @default.
- Q65472656 name "SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)" @default.
- Q65472656 name "SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome" @default.
- Q65472656 type Item @default.
- Q65472656 label "SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)" @default.
- Q65472656 label "SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome" @default.
- Q65472656 prefLabel "SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)" @default.
- Q65472656 prefLabel "SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome" @default.
- Q65472656 P1050 Q65472656-F8B82DF2-CE28-4145-A33E-C9F05F47F727 @default.
- Q65472656 P1132 Q65472656-4E0680CD-D3A9-4300-9F7A-C839BC5475ED @default.
- Q65472656 P1476 Q65472656-943E7956-3BA2-4D5B-81D1-9B71B48CDEE0 @default.
- Q65472656 P17 Q65472656-0059F770-18AC-48BB-8BF1-216CDA7F2D18 @default.
- Q65472656 P17 Q65472656-1FBB890B-572D-4938-BAE7-CF8F2DF36371 @default.
- Q65472656 P17 Q65472656-70ECDBFD-24BB-4975-9594-A5F34F89B284 @default.
- Q65472656 P17 Q65472656-799BCFFD-2025-4B45-AABD-6550CC69F5B2 @default.
- Q65472656 P17 Q65472656-B554C0DB-6274-4B92-99C4-F121CE672E6F @default.
- Q65472656 P17 Q65472656-BDD3FA61-5994-4F95-8F7A-A09E41E5341C @default.
- Q65472656 P17 Q65472656-CA3CD65E-3E76-40C0-AD80-7D00C4348649 @default.
- Q65472656 P17 Q65472656-D4A14C07-81E9-4F89-AD94-8793DEA53975 @default.
- Q65472656 P17 Q65472656-D9A3FC94-B221-404D-85C2-2A0E22BCEB76 @default.
- Q65472656 P2899 Q65472656-9B4BE092-521B-4A71-83D3-EFA1F67CC0DD @default.
- Q65472656 P3098 Q65472656-9A9E0B4F-9195-472C-A65F-84FFB889E2B0 @default.
- Q65472656 P31 Q65472656-132869BB-9922-4997-AE81-C77397A79647 @default.
- Q65472656 P4135 Q65472656-B6CB8095-7FE0-4C3C-B0BA-4E5A2FFD0D0A @default.
- Q65472656 P580 Q65472656-EC781101-577E-440C-9684-7C9F37426F6F @default.
- Q65472656 P582 Q65472656-EA7BF851-3843-4B64-8BEF-1856551AE077 @default.
- Q65472656 P6099 Q65472656-7880DC5A-187A-44DB-BCC3-D52E607A1D47 @default.
- Q65472656 P6153 Q65472656-1E323754-81BF-4282-A724-7C4C92B83BC0 @default.
- Q65472656 P6153 Q65472656-6C3406F5-DDBE-4416-81E1-FF433AE75D50 @default.
- Q65472656 P6153 Q65472656-7A2960E3-AB44-4EE4-819A-DE654DF77B6C @default.
- Q65472656 P6153 Q65472656-ACB0E6E3-0CE8-47E0-9203-F05CFE3C9E78 @default.
- Q65472656 P8363 Q65472656-8A937DB1-5A66-4E91-BBD8-E5843DEEBFDF @default.
- Q65472656 P1050 Q179630 @default.
- Q65472656 P1132 "+550" @default.
- Q65472656 P1476 "A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome" @default.
- Q65472656 P17 Q142 @default.
- Q65472656 P17 Q145 @default.
- Q65472656 P17 Q183 @default.
- Q65472656 P17 Q191 @default.
- Q65472656 P17 Q211 @default.
- Q65472656 P17 Q29 @default.
- Q65472656 P17 Q30 @default.
- Q65472656 P17 Q36 @default.
- Q65472656 P17 Q37 @default.
- Q65472656 P2899 "+20" @default.
- Q65472656 P3098 "NCT00409539" @default.
- Q65472656 P31 Q30612 @default.
- Q65472656 P4135 "+80" @default.
- Q65472656 P580 "2006-12-01T00:00:00Z" @default.
- Q65472656 P582 "2008-06-01T00:00:00Z" @default.
- Q65472656 P6099 Q42824440 @default.
- Q65472656 P6153 Q12364302 @default.
- Q65472656 P6153 Q30270502 @default.
- Q65472656 P6153 Q3145241 @default.
- Q65472656 P6153 Q64442914 @default.
- Q65472656 P8363 Q78089383 @default.